Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice

G. Lopez-Berestein, R. L. Hopfer, R. Mehta, K. Mehta, E. M. Hersh, R. L. Juliano

Research output: Contribution to journalArticlepeer-review

102 Scopus citations


The relative efficacies of free amphotericin B (Amp B) and liposome-encapsulated Amp B (L-AmpB) in the treatment of established Candida albicans infection in mice rendered neutropenic with cyclophosphamide were studied. AmpB was entrapped in multilamellar liposomes composed of dimyristoyl phosphatidylcholine and dimyristoyl phosphatidylglycerol in a molar ratio of 7:3. Infected mice treated with single doses of 3 mg L-AmpB/kg of body weight had an increased survival time compared with those infected with either single (dose, 0.8 mg/kg) or multiple doses (dose, 0.8 mg/kg daily for five days) of free AmpB. When treatment was delayed beyond three days postinfection, neither single nor multiple doses of free AmpB resulted in increased survival, whereas treatment with single-dose L-AmpB (dose, 4 mg/kg) showed efficacy when delayed as much as four days postinfection. Five days postinfection only higher doses (dose, 5.6 mg-11.2 mg/kg) of L-AmpB improved survival time and the renal impairment present in the infected animals. These data provide a rational basis for using high-dose L-AmpB to treat fungal diseases in humans, particularly in neutropenic patients.

Original languageEnglish (US)
Pages (from-to)278-283
Number of pages6
JournalJournal of Infectious Diseases
Issue number2
StatePublished - 1984

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice'. Together they form a unique fingerprint.

Cite this